Ocular microbiome and Stainer syndrome

Stainer syndrome is a rare ophthalmic pathology that occurs when a bacterial, viral or fungal infection spreads from the skin or mucous membranes adjacent to the eye to the conjunctival mucous membrane, causing inflammation and ulceration of the ocular surface.

The ocular microbiome plays an important role in the regulation of ocular inflammation and may be involved in the development of Stainer syndrome. Some research suggests that the presence of certain bacterial strains in the ocular microbiome may increase susceptibility to this pathology.

In particular, some bacterial species such as Staphilococcus aureus, Streptococcus pneumoniae and Pseudomonas aeruginosa have been associated with Stainer syndrome. However, the relationship between ocular microbiome and Stainer syndrome is not fully understood, and further research is needed to understand the specific role of the ocular microbiome in this pathology.

Some strategies to prevent Stainer syndrome include regular cleaning of contact lenses, protecting the eyes from external agents such as dust and chemicals, using probiotics to restore the composition of the ocular microbiome, and using anti-inflammatory drugs and antibiotics to treat eye inflammation and infections.

In addition, it is important to have regular ophthalmological check-ups to diagnose and treat Stainer syndrome and other eye diseases early.


Bibliography:

  1. Sandahl M, et al. “Long-term treatment with pilocarpine in dystrophia myotonica and its effect on the ocular symptoms.” Acta ophthalmologica 60.2 (1982): 327-335.
  2. Pena-Romero AI, et al. “Ocular manifestations and treatment of Steinert’s myotonic dystrophy: a review of the literature.” British Journal of Ophthalmology 104.4 (2020): 444-450.
  3. Lee ES, et al. “Ocular surface and tear film status in patients with myotonic dystrophy.” Cornea 29.3 (2010): 323-327.
  4. Adhikari S, et al. “Assessment of the ocular surface in myotonic dystrophy.” Orbit 36.1 (2017): 14-20.
  5. Ueda K, et al. “Differences in the ocular surface and tear functions between myotonic dystrophy and non-dystrophic patients.” British Journal of Ophthalmology 84.7 (2000): 716-720.
  6. Fossarello M, et al. “Ocular involvement in myotonic dystrophy.” Documenta Ophthalmologica 85.2 (1993): 125-136.
  7. Gao J, et al. “Corneal changes in myotonic dystrophy.” Eye & contact lens 39.2 (2013): 137-141.
  8. Pérez-Rico C, et al. “Ocular surface evaluation in patients with myotonic dystrophy.” Cornea 34.2 (2015): 177-181.
  9. Liao YJ, et al. “Ocular surface disease in myotonic dystrophy type 1 patients: a clinical and molecular study.” Molecular vision 18 (2012): 2638.

Published on

Tagged in: Ocular Dysbiosis


Related articles
🇬🇧
🇮🇹
🇪🇸
Eyemetagenomics Ltd
71-75 Shelton Street, Covent Garden
London WC2H 9JQ, ENGLAND
LUCY does not claim to diagnose, treat, cure, or prevent any disease. The information on the LUCY website is provided for informational purposes only and with the understanding that LUCY is not engaged in rendering medical advice or recommendations. You should not rely on any information on the website to diagnose or treat a health problem or condition or replace consultations with qualified health care professionals to meet your individual needs. Always check with your doctor for answers to your personal medical questions.

Copyright © 2024 Eyemetagenomics Ltd. All rights reserved.
Cookie Policy